BAYER (2023) Aflibercept 8 Mg in Diabetic Macular Edema First to Achieve Sustained Vision Gains with up to 83% of Patients Extended to 16-24 Weeks at Two Years.
https://www.bayer.com/media/en-us/aflibercept-8-mg-in-diabetic-macular-edema-first-to-achieve-sustained-vision-gains-with-up-to-83-of-patients-extended-to--16-24-weeks-at-two-years/

has been cited by the following article:

• TITLE: Progress in the Treatment of DME

  AUTHORS: Xunyu Zou, Yuxuan Liu, Shizhou Cheng, Zuhai Zhang

  KEYWORDS: Diabetic Macular Edema, Anti-Vascular Endothelial Growth Factor, Corticosteroids, Laser Photocoagulation, Vitrectomy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.2, February 6, 2024

  ABSTRACT: Diabetic macular edema (DME) is a common ocular complication of diabetes mellitus (DM) and an important cause of vision loss. The pathogenesis of DME is complex and can occur at any time of diabetic retinopathy (DR). Effective methods of treating DME are essential to prevent irreversible damage to visual function. To date, laser photocoagulation, vascular endothelial growth factor (VEGF) inhibitors, and corticosteroids have demonstrated their therapeutic efficacy in large randomized controlled trials and real-life observational studies. Clinicians need to consider various factors, such as efficacy, safety, accessibility, and cost, in the selection of various options. This review summarizes the current therapeutic approaches for DME to provide new references for the treatment of DM.